Joincare Pharmaceutical Group Industry Co.Ltd(600380) pharmaceutical group share repurchase progress announcement
Stock Code: Joincare Pharmaceutical Group Industry Co.Ltd(600380) Stock Name: Joincare Pharmaceutical Group Industry Co.Ltd(600380) Announcement No.: pro 2022024 Joincare Pharmaceutical Group Industry Co.Ltd(600380)
Announcement on the progress of share repurchase through centralized bidding transaction
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips
● from December 23, 2021 to December 22, 2022, the company expects to repurchase at a price of no more than 15 yuan / share (inclusive), with a total repurchase amount of no less than 300 million yuan (inclusive) and no more than 600 million yuan (inclusive).
● as of March 27, 2022, the company has repurchased 20942771 shares, accounting for 1.10% of the company’s total share capital (1907727908 shares), and the total amount paid is 249971600 yuan (including handling fees). In March 2022, the Company repurchased 7573927 shares in total and paid a total amount of 887096 million yuan (including handling charges).
Joincare Pharmaceutical Group Industry Co.Ltd(600380) (hereinafter referred to as “the company”) held the sixth meeting of the eighth board of directors and the fifth extraordinary general meeting of shareholders in 2021 respectively on December 6, 2021 and December 23, 2021, deliberated and adopted the proposal on repurchase of shares of the company through centralized bidding transaction and other relevant proposals, and agreed that the company use its own funds or self raised funds to repurchase shares of the company through centralized bidding transaction, The shares repurchased this time will be used to reduce the registered capital. The total amount of repurchase funds shall not be less than RMB 300 million (inclusive) and not more than RMB 600 million (inclusive), the repurchase price shall not exceed RMB 15 / share (inclusive), and the repurchase period shall not exceed 12 months from the date of deliberation and approval of the repurchase plan by the general meeting of shareholders of the company. For details, please refer to the announcement of Joincare Pharmaceutical Group Industry Co.Ltd(600380) on the plan of repurchasing the company’s shares by means of centralized bidding transaction (p.2021145) and the report of Joincare Pharmaceutical Group Industry Co.Ltd(600380) on repurchasing the company’s shares by means of centralized bidding transaction (p.2022002).
On January 20, 2022, the Company repurchased 785992 shares for the first time through centralized bidding transaction, accounting for 0.04% of the total share capital of the company. For details, please refer to Joincare Pharmaceutical Group Industry Co.Ltd(600380) Pharmaceutical Group shares disclosed by the company
Joincare Pharmaceutical Group Industry Co.Ltd(600380) pharmaceutical group share repurchase progress announcement
Announcement of the limited company on the first repurchase of the company’s shares by means of centralized bidding transaction (p.2022004). In accordance with the self regulatory guidelines for listed companies of Shanghai Stock Exchange No. 7 – share repurchase and other relevant provisions, the specific progress of the company’s share repurchase is hereby announced as follows:
As of March 27, 2022, the company has repurchased 20942771 shares through centralized bidding, accounting for 1.10% of the company’s total share capital (1907727908 shares). The highest purchase price is 12.91 yuan / share, the lowest price is 10.78 yuan / share, and the total amount paid is 249971600 yuan (including handling fees). In March 2022, the Company repurchased 7573927 shares in total and paid a total amount of 887096 million yuan (including handling charges). The above repurchase is in line with the company’s established share repurchase plan. In the future, the company will implement the share repurchase plan and timely fulfill the obligation of information disclosure in strict accordance with the self regulatory guidelines for listed companies of Shanghai Stock Exchange No. 7 – share repurchase and other relevant provisions. Please pay attention to the investment risks.
It is hereby announced.
Joincare Pharmaceutical Group Industry Co.Ltd(600380) March 28, 2002
